Rationale: Olaratumab is the PDGFRɑ-inhibitor marketed as the long awaited savior for soft-tissue sarcoma, and you’d think a wildly promising phase 2 trial would serve as reason enough to hope for a blockbuster hit with its phase 3 follow-on ANNOUNCE trial. Well, it wasn’t.
Betting Line: Olaratumab doesn’t improve outcomes across a population with unselected unresectable soft-tissue sarcomas. | Tap, ASCO Plenary 2019


Popular Posts